Joshua Chen

发表

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

C. Katlama, J. Gatell, A. Lazzarin, 2007, The Lancet.

A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women.

J. Cuzick, A. Giuliano, S. Kjaer, 2015, The New England journal of medicine.

Assessing consistent treatment effect in a multi‐regional clinical trial: a systematic review

Hui Quan, S Peter Ouyang, Yoko Tanaka, 2010, Pharmaceutical statistics.

An adaptive strategy for assessing regional consistency in multiregional clinical trials

Hui Quan, Paul Gallo, Joshua Chen, 2012, Clinical trials.

Consistency of Treatment Effect across Regions in Multiregional Clinical Trials, Part 2: Monitoring, Reporting, and Interpretation

P. Gallo, H. Quan, Gang Li, 2011 .

Consistency of Treatment Effect across Regions in Multiregional Clinical Trials, Part 1: Design Considerations

P. Gallo, H. Quan, Gang Li, 2011 .

Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccine

E. Moreira, Joshua Chen, E. Moeller, 2015, Human vaccines & immunotherapeutics.

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

H. Teppler, J. Wagner, K. Lasseter, 2008, Antimicrobial Agents and Chemotherapy.

Raltegravir with optimized background therapy for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

D. Hazuda, D. Cooper, H. Teppler, 2007, AIDS.

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

D. Hazuda, B. Clotet, C. Katlama, 2008, The New England journal of medicine.

Raltegravir: the first HIV‐1 integrase strand transfer inhibitor in the HIV armamentarium

D. Hazuda, R. Leavitt, H. Teppler, 2011, Annals of the New York Academy of Sciences.

Evaluation of local treatment effect by borrowing information from similar countries in multi‐regional clinical trials

H. Quan, Joshua Chen, Hua Guo, 2016, Statistics in medicine.

A 9-valent HPV vaccine against infection and intraepithelial Neoplasia in women

J. Cuzick, A. Giuliano, S. Kjaer, 2015 .

Immunogenicity and Safety of a 9-Valent HPV Vaccine

X. Castellsagué, P. van Damme, P. Pitisuttithum, 2015, Pediatrics.

Phase II studies to select the formulation of a multivalent HPV L1 virus-like particle (VLP) vaccine

A. Giuliano, M. Penny, Joshua Chen, 2015, Human vaccines & immunotherapeutics.

Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials

Naitee Ting, P. Gallo, H. Quan, 2013, Clinical trials.

Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine.

Joshua Chen, O. Bautista, E. Moeller, 2015, Contemporary clinical trials.

Treatment with indinavir, efavirenz, and adefovir after failure of nelfinavir therapy.

Joshua Chen, D. Haas, J. Condra, 2003, The Journal of infectious diseases.

Empirical shrinkage estimator for consistency assessment of treatment effects in multi‐regional clinical trials

Hui Quan, Weichung Joe Shih, Peng-Liang Zhao, 2013, Statistics in medicine.

Multiregional Clinical Trials

H. Quan, Joshua Chen, B. Binkowitz, 2017 .

Assessment of Consistency of Treatment Effects in Multiregional Clinical Trials

Hui Quan, Gang Li, Paul Gallo, 2010 .

Impact of Different Regulatory Requirements for Trial Endpoints in Multiregional Clinical Trials

Cynthia J. Girman, Anupam Agarwal, Joshua Chen, 2011 .

R Functions for Sample Size and Probability Calculations for Assessing Consistency of Treatment Effects in Multi-Regional Clinical Trials

Gang Li, Hui Quan, Xiaolong Luo, 2012 .